The Affordable Medicines Facility-malaria (AMFm): are remote areas benefiting from the intervention? by Ye, Yazoume et al.
Ye, Y; Arnold, F; Noor, A; Wamukoya, M; Amuasi, J; Blay, S;
Mberu, B; Ren, R; Kyobutungi, C; Wekesah, F; Gatakaa, H; Toda,
M; Njogu, J; Evance, I; O’Connell, K; Shewchuk, T; Thougher, S;
Mann, A; Willey, B; Goodman, C; Hanson, K (2015) The Afford-
able Medicines Facility-malaria (AMFm): are remote areas benefit-
ing from the intervention? Malar J, 14 (1). p. 398. ISSN 1475-2875
DOI: 10.1186/s12936-015-0904-z
Downloaded from: http://researchonline.lshtm.ac.uk/2324774/
DOI: 10.1186/s12936-015-0904-z
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Ye et al. Malar J  (2015) 14:398 
DOI 10.1186/s12936-015-0904-z
RESEARCH
The Affordable Medicines 
Facility-malaria (AMFm): are remote areas 
benefiting from the intervention?
Yazoume Ye1*, Fred Arnold1, Abdisalan Noor2, Marilyn Wamukoya3, John Amuasi4, Samuel Blay5, 
Blessing Mberu3, Ruilin Ren1, Catherine Kyobutungi3, Frederick Wekesah3, Hellen Gatakaa1, Mitsuru Toda6, 
Julius Njogu7, Illah Evance7, Kathryn O’Connell7, Tanya Shewchuk7, Sarah Thougher8, Andrea Mann8, 
Barbara Willey8, Catherine Goodman8 and Kara Hanson8
Abstract 
Background: To assess the availability, price and market share of quality-assured artemisinin-based combination 
therapy (QAACT) in remote areas (RAs) compared with non-remote areas (nRAs) in Kenya and Ghana at end-line of 
the Affordable Medicines Facility-malaria (AMFm) intervention.
Methods: Areas were classified by remoteness using a composite index computed from estimated travel times to 
three levels of service centres. The index was used to five categories of remoteness, which were then grouped into 
two categories of remote and non-remote areas. The number of public or private outlets with the potential to sell or 
distribute anti-malarial medicines, screened in nRAs and RAs, respectively, was 501 and 194 in Ghana and 9980 and 
2353 in Kenya. The analysis compares RAs with nRAs in terms of availability, price and market share of QAACT in each 
country.
Results: QAACT were similarly available in RAs as nRAs in Ghana and Kenya. In both countries, there was no statisti-
cal difference in availability of QAACT with AMFm logo between RAs and nRAs in public health facilities (PHFs), while 
private-for-profit (PFP) outlets had lower availability in RA than in nRAs (Ghana: 66.0 vs 82.2 %, p < 0.0001; Kenya: 
44.9 vs 63.5 %, p = <0.0001. The median price of QAACT with AMFm logo for PFP outlets in RAs (USD1.25 in Ghana 
and USD0.69 in Kenya) was above the recommended retail price in Ghana (US$0.95) and Kenya (US$0.46), and much 
higher than in nRAs for both countries. QAACT with AMFm logo represented the majority of QAACT in RAs and nRAs 
in Kenya and Ghana. In the PFP sector in Ghana, the market share for QAACT with AMFm logo was significantly higher 
in RAs than in nRAs (75.6 vs 51.4 %, p < 0.0001). In contrast, in similar outlets in Kenya, the market share of QAACT with 
AMFm logo was significantly lower in RAs than in nRAs (39.4 vs 65.1 %, p < 0.0001).
Conclusion: The findings indicate the AMFm programme contributed to making QAACT more available in RAs in 
these two countries. Therefore, the AMFm approach can inform other health interventions aiming at reaching hard-
to-reach populations, particularly in the context of universal access to health interventions. However, further examina-
tion of the factors accounting for the deep penetration of the AMFm programme into RAs is needed to inform actions 
to improve the healthcare delivery system, particularly in RAs.
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Background
Malaria burden remains high in sub-Saharan Africa and 
among various reasons for the sustained high burden of the 
disease in the region is the low uptake of the key malaria 
control interventions, including prompt treatment with rec-
ommended anti-malarial medicines for all the population in 
need, due in part to high cost of drugs [1]. The Global Fund 
to Fight AIDS, Tuberculosis and Malaria (Global Fund) 
hosted a Pilot Phase of the Affordable Medicines Facility-
malaria (AMFm) in 2008 to increase uptake of effective anti-
malarial medicines [2, 3]. AMFm is a financing mechanism 
consisting of: (1) price reductions through negotiations 
with manufacturers of quality-assured artemisinin-based 
combination therapy (QAACT); (2) Global Fund subsidy to 
buyers, through a co-payment to participating manufactur-
ers for purchases made by eligible public, private and non-
governmental organization importers; and, (3) interventions 
to support AMFm implementation and promote appropri-
ate anti-malarial use [2, 3]. Under the AMFm mechanism, 
approved public and private importers or first-line buyers 
buy ACT from manufacturers at the subsidized price rang-
ing from US$0.005 to US$0.220 for a treatment course, and 
then distributed them through the standard public and pri-
vate sector distribution channels [4].
In 2010, the Pilot Phase of the AMFm was launched 
in eight national level programmes in seven countries in 
eastern Africa (Kenya, Uganda and the United Republic 
of Tanzania), western Africa (Ghana, Niger and Nige-
ria), and southern Africa (Madagascar) [2]. About 155.8 
million doses of QAACT financed through AMFm were 
delivered to participating countries from August 2010 to 
December 2011 [5]. In addition to the medicines supplied 
to countries, several supporting interventions were imple-
mented, including population awareness campaigns, set-
ting recommended retail prices and training providers [2] 
to ensure effective implementation of the intervention.
The Global Fund commissioned an independent evalu-
ation (IE) of AMFm to assess the achievement of its four 
objectives of reducing QAACT prices and increasing 
QAACT availability, market share and use at the national 
level in each pilot [5]. The IE used a pre- and post-test 
design and documented the implementation process and 
context in each pilot independently. National outlet sur-
vey of outlets stocking anti-malarial medicines was con-
ducted at the baseline (2009/10) and the endline (2011) in 
each pilot. While assessing the performance of the pro-
gramme at the national level, the Global Fund was also 
interested in knowing if the intervention had reached 
disadvantaged groups, particularly people living in areas 
considered remote. For this reason, the Global Fund 
commissioned a remote area study as part of the IE.
Traditionally, areas are classified as urban and rural 
with the latter often considered remote. However, some 
urban areas may be more remote than other urban areas, 
while some rural areas are more remote than other rural 
areas. Some rural areas that are better connected than 
isolated urban areas in some countries. To account for 
this potential misclassification, for in this study remote-
ness was defined as a function of distance from popula-
tion settlements to service centres.
The remote area study involved a supplementary sam-
ple of remote areas in the AMFm outlet survey at end-
line. It was carried out in two of the pilot phase countries 
considered fast moving in implementing the AMFm 
intervention. Choosing fast-moving countries would 
allow sufficient implementation intensity and time for the 
intervention to have plausibly reached remote areas and, 
therefore, for an assessment to be informative. Fast-mov-
ing countries were expected to have received the co-paid 
medicines, started the intervention and been implement-
ing the supporting interventions for about 12  months 
before the endline survey. At the time of selecting coun-
tries for the study, from all indications, Kenya and Ghana 
were fulfilling these criteria. This expectation was borne 
out by the main evaluation results, which found that 
Ghana and Kenya were among those that achieved sev-
eral AMFm benchmarks.
In Ghana, the availability of QAACT increased by 52 % 
points from baseline to endline, meeting largely the bench-
mark 1 of a 20  % point increase in QAACT availability. 
Similarly, the country met the benchmark 5 of 10 % point 
increase in market share of QAACT with an increase of 
40 % points of QAACT market share from baseline to end-
line. The median price of QAACT with AMFm was three 
times less than the median price of the most popular anti-
malarial, which is not a QAACT in tablet form, just miss-
ing the benchmark 2 less than three times.
Kenya met, largely, the benchmark 1 with an increase 
of 35  % points of availability of QAACT from baseline 
to endline. Market share of QAACT increased signifi-
cantly by 31  % point, meeting the benchmark 5. Com-
pared to Ghana, Kenya met the benchmark 2 (price) with 
the median price of QAACT with AMFm equal to the 
median price of the most popular anti-malarial, which is 
not a QAACT in tablet form [4, 5].
However, the question remained of whether the AMFm 
programme benefitted more remote populations. This 
paper examines the availability, price and market share 
of QAACT in remote areas compared with non-remote 
areas in Kenya and Ghana at the endline of the AMFm 
intervention.
Methods
Study design and defining remoteness
The study was based on a non-experimental design 
comparing remote areas with non-remote areas using 
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cross-sectional data collected from drug outlets in 
Kenya and Ghana. To define remoteness, the authors 
used weighted spatial access to different types of ser-
vices centres as suggested by the Australian Institute 
for Health and Welfare [6, 7]. The authors generated a 
surface of travel time to service centres for Kenya and 
Ghana to define access to these centres and determine 
the degree of remoteness on a continuous surface of 
1  ×  1  km spatial resolution. Access to three layers of 
service centres was determined by assuming that peo-
ple travel to a destination: (a) by walking or using non-
motorized transport (cycling); (b) by walking from the 
place of residence through the landscape to the nearest 
road before finishing the remainder of the journey by 
motorized transport; or, (c) walking only from the ori-
gin along the road.
Population settlements were classified by distance to 
three service centres: Service Centres 1 (market and trad-
ing centres for Kenya; all grid squares with a population 
of 5000–10,000 for Ghana); Service Centres 2 (divisional 
headquarters and towns for Kenya; all grid squares with 
10,000–50,000 population for Ghana); and Service Cen-
tres 3 (cities, municipalities, major towns and district 
headquarters for Kenya; all grid squares with a popula-
tion of at least 50,000 for Ghana). Note, that for Kenya 
the authors used predefined settlement classifications by 
the Ministry of Roads and Public Works that mapped set-
tlements in cities, municipalities, major towns, district 
headquarters, divisional headquarters, towns, market 
centres, and trading centres. For Ghana, because data 
were not readily available, the authors used the gridded 
population surface for 2010 at a resolution of 1 × 1 km 
[8] to define the service centres. It should be noted that 
we do not intend to compare the two countries, rather 
treat each country independently. Therefore, the dif-
ference in definition of remote areas between the two 
countries will not affect the analysis and interpretation of 
results.
The average travel time to any category of service cen-
tres was calculated from the 1 × 1 km grid surfaces for 
the two countries. The time it takes to travel to any cat-
egory of service centres was divided by the average travel 
time to that category from each grid pixel. The result was 
a surface of travel time ratio-to-mean. A grid pixel with a 
ratio-to-mean travel time of 2 to Service Centre 1 implied 
it took twice as long to reach the nearest Service Centre 1 
as it took from the average grid pixel. This ratio for each 
pixel was capped at a value of 0.5 for Kenya and 0.6 for 
Ghana to be equivalent to approximately half-an-hour 
travel time to a Service Centre 1, 1.5 h to a Service Centre 
2 and 2 h to a Service Centre 3. All pixels with the ratio-
to-mean travel time to any service centre of ≥0.5 were 
assigned ratio-to-mean of 0.5 [9] to reduce the effect of 
the longer travel times to larger but fewer service centres 
on the overall index. The sum of the capped ratio-to-
mean surfaces to each type of Service Centre resulted in 
a continuous index of remoteness ranging from 0 to 1.5. 
The continuous surface was classified into five catego-
ries: highly accessible (≤0.3), accessible (>0.3 and ≤0.6), 
moderately accessible (>0.6 and ≤0.9), remote (>0.9 and 
≤1.2), and very remote (>1.2 to 1.5) [7], then collapsed 
into two categories: non-remote (≤0.90) and remote 
areas (>0.90).
Selecting remote area clusters
The IE outlet surveys at baseline and endline used a clus-
ter sampling approach with urban and rural defined as 
domains. Clusters with on average 10,000–15,000 inhab-
itants, were selected randomly with probability propor-
tional to population size [4]. Both baseline and endline 
surveys were powered to generate nationally representa-
tive estimates in rural and urban domains only; there-
fore, they did not include a sufficient number of clusters 
in remote areas to examine outcomes among this type 
of area. Using the final remoteness classification, the 
authors first identified the number of clusters from the IE 
endline outlet survey sample that were located in remote 
areas, and then estimated the number of additional clus-
ters needed in remote areas to have 80 % statistical power 
and a 5 % significance level to detect differences in availa-
bility of co-paid QAACT between remote areas and non-
remote areas, if any [5].
In Kenya, 19 remote area clusters were required: the 
nine clusters identified in the IE endline outlet survey 
and ten additional clusters selected by probability pro-
portional to population size. A total of 15 clusters were 
needed in Ghana: the five clusters identified in the IE 
endline outlet survey and ten additional clusters selected 
by probability proportional to population size. The spatial 
distribution of the clusters is depicted in Fig. 1. Note that 
for Kenya, non-malaria zones were excluded from the 
sampling frame used to select extra remote areas clusters. 
Furthermore the booster sample1 which had been 
included in the IE endline outlet survey was not collected 
in the new remote area clusters [5], because eligible facil-
ities, Part One pharmacies and public health facilities 
were rare in the remote areas.
1 Public health facilities and Part one pharmacies typically serve a large 
number of patients and may be the main providers of QAACT. However, 
few of these outlets were expected to be in any given cluster. Therefore, 
public health facilities and part one pharmacies were oversampled. For 
each sampled subdistrict, public health facilities and part one pharmacies 
found in the district in which the sub-district was located were censused [5], 
AMFm Independent Evaluation Team 2012).
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Data collection
The surveys in the additional remote areas clusters were 
conducted from 27 February to 16 March, 2012 in Kenya 
and 4–13 March, 2012, in Ghana. Data were collected 
using paper-based questionnaires. The tools and proce-
dures used in both countries were similar to those used in 
the IE endline outlet survey described in detail elsewhere 
[5]. In each selected cluster in remote areas, all outlets 
with the potential to sell anti-malarial medicines were 
enumerated. At each outlet, screening questions were 
asked and outlets that had anti-malarial medicines in 
stock or had stocked them in the previous 3 months were 
eligible for the full interview. After oral informed con-
sent from the provider, a comprehensive questionnaire 
was administered. The questionnaire included provider 
characteristics and information on each anti-malarial in 
stock, including its type and retail price. The remote area 
survey took place after the end of the IE endline outlet 
survey. Therefore, a new question (“Have you stocked any 
anti-malarial medicines in the last 4 months? (November 
2011–February 2012”) was added to the questionnaire to 
cover a longer recall period of 4 months to overlap with 
the IE endline outlet survey period October–December 
2011 in both countries [5]. No new data were collected 
in the clusters in non-remote areas or remote areas that 
were covered in the IE endline outlet survey.
Data processing and analysis
Data were entered using Microsoft Access in Kenya and 
Epidata in Ghana. Double entry and preliminary data 
cleaning were performed and data transferred to STATA 
v 11 for final cleaning, preparation of data and analy-
sis. All anti-malarial medicines audited were classified 
into non-artemisinin therapy, artemisinin monotherapy 
(AMT), and artemisinin combination therapy (ACT). 
ACT included QAACT, with or without the AMFm 
logo, and non-QAACT. The QAACT with the AMFm 
logo were the co-paid medicines [5]. This paper reports 
anti-malarial medicine price and market share in adult 
equivalent treatment doses (AETDs), defined as the 
amount needed to treat a 60-kg adult. Market share was 
calculated by dividing the number of AETDs of a specific 
anti-malarial medicine category sold by the total num-
ber of AETDs of all anti-malarial medicines sold. Price 
data were collected in country currencies and adjusted to 
2010 prices using national consumer price indices, then 
converted to US$ using the average interbank exchange 
rate for 2010 [4].
Fig. 1 Remoteness classification map showing the location of clusters sampled in the remote areas for the AMFm Independent Evaluation remote 
area survey, 2012
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The analysis compares remote areas with non-remote 
areas in terms of availability, price and market share of 
QAACT in each country. Since booster sample was not 
included in the remote area survey, it was also removed 
from the non-remote areas before analysis. The signifi-
cance of the differences between remote areas and non-
remote areas was assessed using Chi squared tests for 
proportions and Wilcoxon rank sum tests for price indi-
cators, expressed as medians. All the estimates in Kenya 
were weighted to account for the complex survey design. 
In Ghana, the estimates were not weighted because it was 
not possible to calculate the weight due to a lack of an 
estimate of the remote areas’ share of the total population 
[5]. Possible implications for the estimates are mentioned 
in the discussion.
Ethical approval
Ethical approval was obtained from national ethics com-
mittees in Ghana and Kenya, and Institutional Review 
Boards of ICF International and the London School of 
Hygiene and Tropical Medicine.
Results
Description of the study sample
In Ghana, for the additional remote area survey, inter-
views were conducted in all 129 outlets that met the 
screening criteria, of which 117 were stocking anti-
malarial medicines at the time of the survey visit. From 
the remote area clusters identified in the IE endline outlet 
survey, 32 outlets were stocking anti-malarial medicines. 
Therefore, 149 remote area outlets were included in the 
analysis. For the non-remotes, 487 outlets from the IE 
endline outlet survey that were stocking anti-malarial 
medicines were included in the analysis.
In Kenya, in the additional remote area survey, a much 
larger number of outlets was enumerated overall (3048) 
because in contrast to the case of Ghana, a broader 
grouping of outlets was classified as having the potential 
to sell anti-malarial medicines and thus were enumer-
ated. For example, general retailers were systematically 
enumerated in Kenya but not Ghana. Interviews were 
conducted in 318 outlets, and 271 were stocking anti-
malarial medicines at the time of the survey visit. From 
the remote area clusters identified in the IE endline out-
let survey, 125 outlets were stocking anti-malarial medi-
cines. The total sample for remote areas was therefore 
396 outlets. For non-remote areas, 1223 outlets from the 
IE endline outlet survey were stocking anti-malarial med-
icines (Table 1).
Of the 149 outlets with anti-malarial medicines in 
Ghana, almost two-thirds (97) were private for-profit 
outlets and about one-sixth (26) were public health facili-
ties. A similar pattern was observed in Kenya, where 
private for-profit outlets represented 82.8  % (328) of all 
outlets with anti-malarial medicines, followed by public 
health facilities. In contrast to Ghana, where 22 commu-
nity health workers had anti-malarial medicines in stock, 
in Kenya only one community health workers reported 
having anti-malarial medicines in stock (Table 2).
Availability of quality‑assured artemisinin combination 
therapy
Public health facilities in both countries had statisti-
cally similar levels of availability in remote areas and 
Table 1 Number of  remote and  non-remote area outlets enumerated and  number stocking antimalarials at  the time 
of the survey in Ghana and Kenya, 2011–2012
a Data collection period: Ghana: November 7–28, 2011, Kenya: October 7–December 10, 2011
b Data collection period: Ghana: March 4–13, 2012, Kenya: February 27–March 16, 2012
Country/period of data 
collection
Outlets enumerated Outlets screened Outlets which met 
screening criteria
Outlets in which inter‑
views were conducted
Outlets stocking anti‑
malarials at the time 
of the survey visit
Ghana
 Remote areas, total 221 194 164 164 149
  In additional surveya 161 147 129 129 117
  In endline surveyb 60 47 35 35 32
 Non-remote areas only  
in endline survey
– – 506 506 487
Kenya
 Remote areas, total 4244 3241 468 468 396
  In additional surveya 3048 2353 318 318 271
  In endline surveyb 1196 888 150 150 125
 Non-remote areas only  
in endline survey
– – 9980 9980 1223
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non-remote areas (Ghana: 96.2 vs 80.0 %, p = 0.0645 and 
Kenya: 95.4 vs 96.4 %, p = 0.9999). Private for-profit out-
lets presented a different picture, with significantly lower 
availability of QAACT in remote areas in both coun-
tries (Ghana: 68.0 vs 84.1 %, p < 0.0001 and Kenya: 45.9 
vs 65.5 %, p < 0.0001). In both countries, most outlets in 
all areas had QAACT in stock. However, in Ghana there 
was no significant difference in availability of QAACT in 
all types of outlets combined between remote areas and 
non-remote areas. In Kenya, the availability of QAACT 
in all types of outlets combined was significantly lower in 
remote areas than in non-remote areas (56.2 vs 70.8  %, 
p < 0.0001).
In public health facilities in both countries, there was 
no statistical difference in availability of QAACT with the 
AMFm logo between remote areas and non-remote areas 
(Ghana: 84.6 vs 76.4 %, p = 0.3951 Kenya: 60.5 vs 68.9 %, 
p = 0.9913). In both countries, private for-profit outlets 
had lower availability of QAACT with the AMFm logo in 
remote areas than in non-remote areas (Ghana: 66.0 vs 
82.2 %, p < 0.0001; Kenya: 44.9 vs 63.5 %, p = <0.0001). 
The availability of QAACT with the AMFm logo was 
significantly lower in all types of outlets combined in 
remote areas than in non-remote areas in both countries. 
Nevertheless, in remote areas almost half the outlets in 
Ghana and 60 % in Kenya had QAACT with the AMFm 
logo. It should be noted that availability of all QAACT 
is very similar to QAACT with AMFm logo as most of 
QAACT in private for-profit outlets were AMFm-subsi-
dized QAACT (Table 3).
Pricing of quality‑assured artemisinin combination therapy
In Ghana, public health facilities and private for-profit 
outlets, the median cost to patients of one AETD of all 
QAACT in all formulations (adult and children) was not 
significantly different between remote areas and non-
remote areas (public health facilities: US$0.94 vs US$0.94, 
p = 0.3742; private for profit outlets: US$1.25 vs US$1.25, 
p =  0.9742). In Kenya, the median price of QAACT was 
zero in public health facilities that are required to provide 
ACT for free, in remote areas and non-remote areas. How-
ever, the private for-profit outlets in remote areas were 
selling QAACT at nearly twice the price as in non-remote 
areas (US$0.81 vs US$0.46, p < 0.0001). Regarding QAACT 
with the AMFm logo, in both countries the median price 
for PHFs was similar in remote areas and non-remote 
areas. However, in Kenya the median price of QAACT with 
the AMFm logo was much higher in remote areas for pri-
vate for-profit outlets than in non-remote areas (US$0.69 
vs US$0.46, p  <  0.0001). Similarly in Ghana, private for-
profit in remote areas were selling QAACT with AMFm 
logo US$0.25 higher than non-remote areas (Table 4).
The median price of a paediatric formulation2 of all 
QAACT for public health facilities and private for-profit 
outlets did not differ between remote areas and non-
remote areas in Ghana and Kenya. Similarly, in both 
countries the median price paediatric formulation of 
QAACT with the AMFm logo in public health facilities 
and private for-profit outlets was the same in remote 
areas and non-remote areas (Table 5).
Market share for QAACT
In the private for-profit PFP sector alone, in Ghana, 
QAACT had the dominant market share in remote 
areas and non-remote areas, but the market share for 
QAACT was significantly higher in remote areas than in 
non-remote areas (75.6 vs 51.5  %, p  <  0.0001) and close 
to 100 % of the QAACT had the AMFm logo. In Kenya, 
in the private for-profit outlets, the market share of 
QAACT was significantly lower in remote areas than in 
non-remote areas (40.0 vs 67.0 %, p < 0.0001) and nearly 
all the QAACT had the AMFm logo (Fig. 2a). In Ghana, 
across all outlets, the market share of QAACT was similar 
in remote areas (58.8 %) and non-remote areas (55.7 %). 
Non-artemisinin therapy had the second highest mar-
ket share in remote areas and non-remote areas (25.0 vs 
20.2 %). In Kenya, the market share for QAACT was sig-
nificantly lower in remote areas than in non-remote areas 
(48.0 vs 58.4  %, p  <  0.0001). In both countries, QAACT 
with the AMFm logo represented the majority of QAACT 
in remote areas and non-remote areas (Fig. 2b).
Discussion
The study compared the availability, price and market 
share of QAACT in remote areas and non-remote areas, 
2 Unit-dose packages intended for a 2-year old/10-kg child.
Table 2 Number of  outlets with  antimalarials in  stock 
by  type of  outlet in  the remote and  non-remote areas 
in Ghana and Kenya, 2011–2012
Country/type of outlets Remote areas Non‑remote areas
Ghana, total 149 487
 Public health facility 26 55
 Private not-for-profit health 
facility
4 10
 Private for-profit outlet 97 422
 Community health worker 22 0
Kenya, total 396 1223
 Public health facility 52 105
 Private not-for-profit health 
facility
15 43
 Private for-profit outlet 328 1075
 Community health worker 1 0
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defined as distance and travel time to major service cen-
tres, at the endline of the AMFm pilot phase in Ghana 
and Kenya. Although there had been considerable uncer-
tainty about whether AMFm would reach remote areas, 
the results presented here confirm that remote areas ben-
efitted from the intervention to a considerable extent.
Although the availability of QAACT was lower in 
remote areas than in non-remote areas, the medicines 
were widely available in remote areas in Ghana and Kenya 
at the endline. The availability of QAACT was particularly 
high in public health facilities; however, substantial private 
for profit outlets and most medicines were QAACT with 
the AMFm logo in both countries. Overall, the findings 
suggest that the AMFm programme was instrumental in 
making QAACT more available in remote areas in these 
countries. Yadav and colleagues reported similar finding 
in Tanzania where AMFm led to a large increase in the 
availability of QAACT with the AMFm logo in the coun-
try, with variation based on remoteness [10]. In Kenya and 
Ghana, reliable distribution systems, particularly in the 
private sector, could have played a major role in making 
the medicines available in remote areas. Ghana and Kenya 
are among the countries that met the AMFm benchmark 
indicator of a 20 % point increase in QAACT availability 
from the baseline to the endline [4].
The median price of QAACT (adult and children’s 
formulations) in remote areas and non-remote areas 
was similar in Ghana. On the other hand in Kenya, the 
median price of QAACT was US$0.46 in non-remote 
areas and almost zero in remote areas. The near-zero 
median price in remote areas in Kenya is driven by the 
substantial number of public health facilities where the 
drug is mostly free. In contrast, patients paid for QAACT 
in public health facilities in Ghana [5]. However, there 
was no difference in the median price of QAACT pediat-
ric formulation in the public health facilities and private 
for-profit outlets between remote areas and non-remote 
areas in both countries. These findings are very comfort-
ing as for Ghana and Kenya children under-five are the 
most vulnerable to malaria infection.
Table 3 Outlets in remote areas and non-remote areas with quality-assured artemisinin combination therapies in stock 
at endline in Ghana and Kenya, 2011–2012
Percentages indicate the percentage of outlets in remote areas and non-remote areas that had quality-assured ACTs in stock at the time of the survey visit (n) 
among all outlets with any antimalarial in stock at the time of the survey visit (N), by type of outlet, according to country, 2011–2012. CI: Confidence interval; 
AMFm = Affordable Medicine Facility-malaria
* p value for Chi square testing for difference between remote and non-remote areas
a These are presented in the table because they contribute to the country overall estimates; however, they are not discussed in the text because of the small sample
Country/Type of outlet Remote areas Non‑remote areas p value*
Percentage (95 % CI) N Percentage (95 % CI) N
All QAACTs
 Ghana, total 77.9 (67.0–85.9) 149 83.8 (78.8–87.8) 487 0.1634
  Public health facility 96.2 (74.5–99.5) 26 80.0 (63.6–90.1) 55 0.0645
  Private not-for-profit health facilitya 100.0 4 90.0 (57.5–98.4) 10 –
  Private for-profit outlet 68.0 (47.6–83.3) 97 84.1 (78.5–88.5) 422 <0.0001
  Community health workera 95.5 (80.0–99.1) 22 – 0 –
 Kenya, total 56.2 (43.4–68.2) 392 70.8 (63.8–76.8) 1223 <0.0001
  Public health facility 95.4 (82.2–98.9) 51 96.4 (89.9–98.8) 105 0.9999
  Private not-for-profit health facilitya 100.0 15 98.6 (93.1–99.7) 43 0.561
  Private for-profit outlet 45.9 (30.0–62.6) 325 65.5 (57.2–72.9) 1075 <0.0001
  Community health workera 100.0 1 – 0 –
QAACTs with AMFm Logo
 Ghana, total 60.4 (37.7–79.3) 149 81.5 (76.7–85.6) 487 <0.0001
  Public health facility 84.6 (65.6–94.1) 26 76.4 (59.4–87.7) 55 0.3951
  Private not-for-profit health facilitya 100.0 4 80.0 (49.4–94.2) 10 –
  Private for-profit outlet 66.0 (45.9–81.6) 97 82.2 (76.9–86.5) 422 <0.0001
  Community health workera 0.0 22 0 –
 Kenya, total 48.5 (36.2–61.0) 392 64.0 (56.3–71.0) 1223 <0.0001
  Public health facility 60.5 (44.6–74.4) 51 68.9 (54.0–80.8) 105 0.9913
  Private not-for-profit health facility 73.3 (44.0–90.6) 15 58.8 (37.0–77.6) 43 0.3622
  Private for-profit outlet 44.9 (29.2–61.8) 325 63.5 (55.6–70.8) 1075 <0.0001
  Community health worker 100.0 1 – 0 –
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At the inception of the AMFm, there were concerns the 
price of QAACT with AMFm logo will be higher than the 
recommended retail price in the private sector in remote 
areas due to potential challenges and additional cost for dis-
tribution, and limited competition. However, in Ghana and 
Kenya, the median retail price for QAACT with AMFm 
logo in private for profit outlets were in line with the rec-
ommended retail price (US$0.94) in Ghana and in Kenya 
(US$0.46). Despite the challenges and additional cost related 
to distribution of the medicines in remote areas, private sec-
tor provider mark-up was not excessive. These findings are 
in line with those by Yadav and colleagues in Tanzania main-
land where they found no difference in price of QAACT with 
AMFm logo between remote areas and non-remote areas 
[9]. In Ghana and Kenya, several factors could have contrib-
uted to widespread compliance to the recommended retail 
price for co-paid QAACT; significant participation by the 
private sector in the AMFm implementation process in both 
countries is likely to have been a contributing factor.
In Ghana, although several anti-malarial medicines 
were on the market, for all sectors combined there was 
no difference between remote areas and non-remote 
areas in the market share of QAACT. However the mar-
ket dominance of QAACT in the private for-profit sec-
tor, especially in remote areas, suggests that the increased 
availability and reduced price may have increased com-
munity awareness of QAACT, resulting in its higher level 
of (relative) sales. In contrast, in Kenya in the private 
for-profit outlets in remote areas, the market share was 
dominated by non-artemisinin therapy. The lower mar-
ket share of QAACTs in the private for-profit outlets in 
remote areas is probably due to the higher price. Never-
theless, as in Ghana, Kenya achieved the AMFm market 
share benchmark of a 10 % point increase in market share 
of QAACT [4]. A possible explanation for the relatively 
low uptake of QAACT in RAs compared with nRAs in 
Kenya could be a lack of community awareness of the 
AMFm programme in remote areas.
Table 4 Median cost to patients of one adult equivalent treatment dose of all formulations (adults and children) of qual-
ity-assured artemisinin combination therapies in  remote areas and  non-remote areas at  endline in  Ghana and  Kenya 
in US dollars, 2011–2012
IQR interquartile range, N number of products audited, AMFm affordable medicine facility-malaria
* p value for Wilcoxon rank sum test for difference between remote and non-remote areas
a These are presented in the table because they contribute to the country overall estimates; however, they are not discussed in the text because of the small sample
Country/type of outlet Remote areas Non‑remote areas p value*
Median cost (IQR) N Median cost (IQR) N
All QAACTs
 Ghana, total 1.25 (0.94–1.88) 187 0.95 (0.94–1.88) 923 0.0652
  Public health facility 0.95 (0.94–1.88) 46 0.94 (0.94–0.94) 66 0.3742
  Private not-for-profit health facilitya 0.94 (0.00–0.94) 5 0.94 (0.00–0.94) 20 0.2113
  Private for-profit outlet 1.25 (0.94–1.88) 114 1.25 (0.94–1.88) 837 0.9742
  Community health workera 1.25 (1.25–1.50) 22 – 0 –
 Kenya, total 0.00 (0.00–0.69) 412 0.46 (0.00–0.61) 1864 <0.0001
  Public health facility 0.00 (0.00–0.00) 182 0.00 (0.00–0.00) 342 –
  Private not-for-profit health facility 0.00 (0.00–0.31) 46 0.00 (0.00–1.04) 116 0.2534
  Private for-profit outlet 0.81 (0.46–1.38) 180 0.46 (0.46–0.92) 1406 <0.0001
  Community health workera 1.73 (1.15–3.45) 4 – 0 –
QAACTs with AMFm logo
 Ghana, total 1.00 (0.94–1.88) 156 0.94 (0.94–1.88) 845 0.1121
  Public health facility 0.94 (0.94–1.25) 39 0.94 (0.94–0.94) 62 0.0624
  Private not-for-profit health facilitya 0.94 (0.00–0.94) 5 0.94 (0.00–0.95) 19 0.1971
  Private for-profit outlet 1.25 (0.94–1.88) 112 1.00 (0.94–1.88) 764 0.0363
  Community health workera – 0 – 0 –
 Kenya, total 0.46 (0.00–1.15) 292 0.46 (0.46–0.69) 1539 0.2423
  Public health facility 0.00 (0.00–0.00) 90 0.00 (0.00–0.00) 156 –
  Private not-for-profit health facility 0.00 (0.00–0.31) 26 0.46 (0.00–0.69) 45 0.2612
  Private for-profit outlet 0.69 (0.46–1.38) 172 0.46 (0.46–0.92) 1338 <0.0001
  Community health workera 1.73 (1.15–3.45) 4 – 0 –
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There are a number of limitations that should be 
considered when using the findings. Remoteness was 
defined as distance and travel time to service centres. 
The assumptions underlying the travel times assigned to 
different land surfaces may vary by country-specific con-
text and may therefore, overestimate or underestimate 
remoteness. Secondly, the outlet survey relied on self-
reports of sales volume and prices with potential recall or 
reporting bias. The authors tried to minimize the recall 
bias by asking for reported sales volumes only for the 
week preceding the survey; however, recall may still have 
been imperfect [11]. Thirdly, the additional remote area 
outlet survey was conducted in the low malaria transmis-
sion season, and non-remote area data collected during 
a higher transmission season in both countries, there-
fore, some of the differences between remote areas and 
non-remote areas might be due to differences in data col-
lection dates. Fourthly, the comparison of remote areas 
versus non-remote areas was only undertaken for Ghana 
and Kenya, which were the best-performing countries 
overall in AMFm; their experience in remote areas may 
have been different in countries with poorer AMFm out-
comes. Finally, the lack of weights for Ghana may have 
created bias in the comparison between remote areas and 
non-remote areas in that country, as most of the larger 
outlets most likely to have QAACT were probably in 
non-remote areas.
Conclusion
Despite the challenges in geographical access posed 
by remote areas and the relatively short intervention 
period, the results show that the AMFm intervention 
has been able to reach remote areas in Ghana and Kenya. 
Although this cross-sectional evidence does not permit 
strong inference about changes over time, it is likely that 
the availability of QAACT increased in remote areas, 
as the majority of QAACT were those with the AMFm 
logo, not available at IE baseline. However, even though 
co-paid medicines was available in remote areas in the 
private for profit sector, availability remained lower, price 
Table 5 Median cost to  patients of  a pediatric dose (unit-dose packages specifically intended to  treat a 2  year/10  kg 
child) formulation of  quality-assured artemisinin combination therapies in  remote areas and  non-remote areas at  the 
endline in Ghana and Kenya, in US dollars, 2011–2012
IQR interquartile range, N number of products, AMFm affordable medicine facility-malaria
** p value for Wilcoxon rank sum test for difference between remote and non-remote areas
a These are presented in the table because they contribute to the country overall estimates; however, they are not discussed in the text because of the small sample
Country/type of outlet Remote areas Non‑remote areas p value**
Median cost (IQR) N Median cost (IQR) N
All QAACTs
 Ghana, total 0.38 (0.31–0.63) 50 0.63 (0.63–0.94) 156 0.0102
  Public health facility 0.28 (0.24–0.47) 12 0.24 (0.24–0.47) 5 0.7121
  Private not-for-profit health facilitya – 0 0.59 (0.24–0.94) 2 –
  Private for-profit outlet 0.63 (0.63–0.94) 19 0.63 (0.63–0.94) 149 0.7731
  Community health workera 0.31 (0.31–0.38) 19 – 0 –
 Kenya, Total 0.00 (0.00–0.46) 65 0.35 (0.00–0.46) 254 <0.0001
  Public health facility 0.00 (0.00–0.00) 27 0.00 (0.00–0.00) 41 –
  Private not-for-profit health facilitya 0.00 (0.00–0.23) 10 0.00 (0.00–0.46) 14 0.8642
  Private for-profit outlet 0.46 (0.35–0.58) 27 0.46 (0.35–0.46) 199 0.2123
  Community health workera 0.58 1 – 0 –
QAACTs with AMFm logo
 Ghana, total 0.63 (0.42–0.84) 24 0.63 (0.63–0.94) 147 0.4033
  Public health facility 0.24 (0.24–0.47) 7 0.24 (0.24–0.43) 4 0.9041
  Private not-for-profit health facilitya – 0 0.59 (0.24–0.94) 2 –
  Private for-profit outlet 0.63 (0.63–0.94) 17 0.63 (0.63–0.94) 141 0.8613
  Community health workera – 0 – 0 –
 Kenya, total 0.00 (0.00–0.46) 52 0.35 (0.23–0.46) 212 <0.0001
  Public health facility 0.00 (0.00–0.00) 21 0.00 (0.00–0.00) 19 0.4845
  Private not-for-profit health facilitya 0.00 (0.00–0.00) 4 0.00 (0.00–0.58) 6 0.7213
  Private for-profit outlet 0.46 (0.35–0.58) 26 0.46 (0.35–0.46) 187 0.2731
  Community health workera 0.58 1 – 0 –
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higher, and (in Kenya) market share was lower than in 
non-remote areas.
The health care delivery system could learn from this 
success and the challenges in the private sector, and 
could adapt a similar approach to adequately cover 
remote and hard-to-reach populations with other inter-
ventions. However, further examination of the fac-
tors accounting for the deep penetration of the AMFm 
programme into remote areas is needed to inform 
actions to improve the health sector commodities distri-
bution systems.
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